Gainers
Kala Pharmaceuticals, Inc. (NASDAQ: KALA) shares gained 130.5% to $9.03 after the company announced FDA acceptance of a IND application for its KPI-012 for the treatment of persistent corneal epithelial defect.
Jason Calacanis helped solidify his spot in the investing world with lucrative early stakes in companies like Uber Technologies (NASDAQ: UBER), Trello, Robinhood Markets (NASDAQ: HOOD<